{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:18:26Z","timestamp":1790194706995,"version":"4.1.0"},"reference-count":45,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Hepatol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Chronic hepatitis B (CHB) affects &gt; 300 million people worldwide. The combination of CHB and cardiometabolic co-morbidities increases the risk of liver-related morbidity and mortality. However, international guidelines for CHB treatment do not provide recommendations for follow-up examinations or treatment of patients with CHB and cardiometabolic comorbidities. In studies investigating cardiometabolic co-morbidity in patients with CHB, inconsistent findings have been observed, and both lower and higher prevalence of cardiometabolic co-morbidities compared to the general population have been reported. It is unclear whether patients with CHB living in Denmark have an increased prevalence of cardiometabolic co-morbidities.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To investigate the prevalence of cardiometabolic comorbidities in patients with CHB and matched non-CHB comparison group.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>We examined patients with CHB and age-, sex-, body mass index (BMI)-, and country-of-birth matched comparison group. Defining cardiometabolic co-morbidity: Obesity (BMI &gt; 25 kg\/m2\/abnormal waist-to-hip ratio), metabolic dysfunction-associated steatotic liver disease (MASLD), hypercholesterolemia (total-cholesterol &gt; 5 mmol\/L\/statin use), hypertension (systolic \u2265 135 mmHg\/ diastolic \u2265 85 mmHg\/antihypertensive medication) and type 2 diabetes (T2D) (2-hour oral glucose tolerance test glucose &gt; 11.1 mmol\/L\/HbA1c &gt; 48 mmol\/mol\/ antidiabetic medication). Physical activity was evaluated using maximal oxygen consumption (VO2max), activity monitors, and a questionnaire.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>We included 98 patients with CHB and 49 persons in the comparison group. The two groups were well-matched, showing no significant differences in age, sex, BMI, country-of-birth, education, or employment. Among patients with CHB, the following prevalence of cardiometabolic co-morbidity was found: 77% were obese, 45% had MASLD, 38% had hypercholesterolemia, 26% had hypertension, and 7% had T2D, which did not differ significantly from the comparison group, apart from lower prevalence of hemoglobin A1c (HbA1c) \u2265 48 mmol\/L or known T2D. Both groups had low VO2max of 27 mL\/kg\/minute in the patients with CHB and 30 mL\/kg\/minute in the comparison group, and the patients with CHB had a shorter self-assessed sitting time.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>The patients with CHB and the comparison group were well-matched and had a similar prevalence of cardiometabolic comorbidities. Furthermore, both groups had low levels of physical fitness.<\/jats:p>","DOI":"10.4254\/wjh.v17.i1.97797","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T01:52:25Z","timestamp":1736128345000},"source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of cardiometabolic co-morbidities in patients with <i>vs<\/i> persons without chronic hepatitis B: The FitLiver cohort study"],"prefix":"10.4254","volume":"17","author":[{"given":"Sofie","family":"Jespersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Fritt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente K","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Krogh-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00124-8"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027696"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.002"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13253"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i25.4587"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i28.3163"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1081"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.8.1844"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15867"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.001"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-1131"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13142"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13713"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07385-y"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818805074"},{"key":"B18","unstructured":"Radcliffe Department of Medicine.   HOMA2 calculator. [cited 13 September 2024]. Available from: https:\/\/www.rdm.ox.ac.uk\/about\/our-clinical-facilities-and-units\/DTU\/software\/homa"},{"key":"B19","unstructured":"World Health Organization (WHO).   Waist circumference and waist\u2013hip ratio: report of a WHO expert consultation, Geneva, 8\u201311 Dec 2008. [cited 13 September 2024]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/44583\/9789241501491_eng.pdf?sequence=1"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-0975-x"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"B24","unstructured":"International Diabetes Federation.   IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care. 2017. [cited 3 September 2024]. Available from: https:\/\/idf.org\/media\/uploads\/2023\/05\/attachments-63.pdf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00078.2023"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/hjb27"},{"key":"B27","doi-asserted-by":"crossref","unstructured":"Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381","DOI":"10.1249\/00005768-198205000-00012"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/00005768-199805000-00021"},{"key":"B29","unstructured":"Br\u00f8nd JC.   PhysAccel package. [cited 13 September 2024]. Available from: https:\/\/github.com\/jbrond\/PhysAccel"},{"key":"B30","unstructured":"The Danish Health Authority.   Danskernes sundhed \u2013 Den Nationale Sundhedsprofl 2021. 2022. [cited 13 September 2024]. Available from: https:\/\/www.sst.dk\/-\/media\/Udgivelser\/2022\/Sundhedsprofil\/Sundhedsprofilen.ashx"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00847-5"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2009.07.038"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2022.2125065"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.003"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.079"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023445"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2008.08.001"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32835168c0"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001071"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018697"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2020-102955"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143424"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202310_33959"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000135174.63482.43"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i1\/97797.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i1\/97797.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T01:52:41Z","timestamp":1736128361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v17\/i1\/97797.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":45,"journal-issue":{"issue":"1"},"alternative-id":["97797"],"URL":"https:\/\/doi.org\/10.4254\/wjh.v17.i1.97797","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}